Compare J & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | J | WST |
|---|---|---|
| Founded | 1947 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 20.1B |
| IPO Year | N/A | N/A |
| Metric | J | WST |
|---|---|---|
| Price | $140.90 | $280.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $155.90 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 1.3M | 661.6K |
| Earning Date | 11-20-2025 | 10-23-2025 |
| Dividend Yield | ★ 0.91% | 0.31% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | 2.38 | ★ 6.75 |
| Revenue | ★ $12,029,783,000.00 | $3,017,900,000.00 |
| Revenue This Year | N/A | $7.01 |
| Revenue Next Year | $6.38 | $6.20 |
| P/E Ratio | $54.35 | ★ $41.51 |
| Revenue Growth | 4.60 | ★ 4.92 |
| 52 Week Low | $106.23 | $187.43 |
| 52 Week High | $168.44 | $348.90 |
| Indicator | J | WST |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 55.28 |
| Support Level | $132.75 | $269.08 |
| Resistance Level | $136.73 | $285.54 |
| Average True Range (ATR) | 5.13 | 7.15 |
| MACD | 0.35 | 1.29 |
| Stochastic Oscillator | 49.27 | 82.62 |
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.